NEUROINFLAMMATION EXPLAINED

What Neuroinflammation Is

Microglia are the immune cells of the brain, comprising roughly 10-15 percent of all brain cells. In healthy young brain tissue, microglia are mostly in a surveillance state -- they extend and retract processes through the surrounding tissue, looking for damaged cells, pathogens, or misfolded proteins to clear. When they detect something that needs cleanup, they switch to an activated state, change their morphology, and release inflammatory cytokines (TNF-alpha, IL-1-beta, IL-6) to coordinate the immune response.

Acute microglial activation is normal and protective. Chronic microglial activation -- which happens with age, with chronic oxidative stress, and in neurodegenerative disease -- is the cellular signature of neuroinflammation². Chronically activated microglia release inflammatory cytokines continuously, damage surrounding neurons through bystander effects, and contribute to the cognitive decline associated with aging brain tissue.

What Drives Chronic Microglial Activation

The major triggers include accumulated misfolded proteins (such as amyloid-beta in Alzheimer's), chronic oxidative stress, gut-derived inflammatory signals that cross a leaky blood-brain barrier, and direct neuronal damage from various sources including alcohol exposure. The NLRP3 inflammasome is a key intracellular complex that microglia use to mount the inflammatory response, and chronic NLRP3 activation is one of the cellular fingerprints of neuroinflammation¹.

(this is the part of the brain-aging story that is most actionable, because microglial activation is one of the few brain-aging markers that supplements have demonstrated effects on in animal data.)

What DHM Does to Microglia

In APP/PS1 transgenic mice (a standard Alzheimer's-disease model), DHM administration suppressed activation of the NLRP3 inflammasome in microglia and reduced markers of neuroinflammation¹. The effect is documented in animal models of neurodegeneration, in the published preclinical work at least. The mechanism involves both direct effects on microglial signaling and indirect effects through reduced amyloid-beta accumulation (DHM appears to promote clearance of amyloid-beta, which removes one of the major triggers for microglial activation in the first place).

The 2019 review of DHM in brain aging and neurodegenerative disease covers the broader microglial-suppression literature across multiple disease models -- Alzheimer's, Parkinson's, Huntington's -- and finds the anti-neuroinflammatory effect is consistent across them².

What This Means for the Brain-Aging Claim

Brain aging in animal studies is typically operationalized as a combination of cognitive performance, oxidative stress markers, neuroinflammation markers, and synaptic protein levels. The microglial-activation marker is one of the four, and DHM moves it in the protective direction in the published mouse data³. The mass-spec evidence that DHM reaches brain tissue intact after oral dosing⁴ establishes that the in-vivo brain effects observed in animal studies are at least plausibly mediated by direct DHM action rather than only by metabolites or indirect peripheral effects.

What This Page Is Not Claiming

The neuroinflammation claim is bounded ot occasional support, not to treatment of any neurodegenerative disease adn that boundary matters. The DHM brain-aging research is preclinical, with no human clinical trials of DHM for cognitive outcomes. We are not claiming H180 prevents Alzheimer's disease, treats any clinical neurodegeneration, or replaces medical care for cognitive symptoms.

For the broader brain-aging claim mapping, see The Brain Aging Claim. For the related inflammation claim covering peripheral inflammation, see The Inflammation Response Claim.